Genfit AASLD KOL Event Nov 2018 in SF

San Francisco/Los Angeles, November 11, 2018

Expert speakers to discuss elafibranor including ongoing Phase 3 trial in NASH and Phase 2a trial in PBC


Expert KOL Speakers to Include:

Stephen A. Harrison, MD, FACP, FAASLD, COL(ret.), USA, MC
Visiting Professor of Hepatology, Radcliffe College of Medicine, University of Oxford
Medical Director, Pinnacle Clinical Research

Dr. Jörn M. Schattenberg
Universitätsmedizin Mainz, Germany

RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Genfit SA [GNFTF] US$637 MM MCap
Lead pro­gram Ela­fi­branor is PPAR al­pha/del­ta ag­on­ist in Ph 3 for NASH and Ph 2 for PBC. Ful­ly en­rolled in Ph 3 RE­SOLVE-IT trial for NASH w da­ta exp YE 2019. Ph 2 PBC da­ta exp YE 2018. On­go­ing NASH... [more in­for­ma­tion]